{"id":"sham-injection-laser","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The sham injection serves as a placebo control, while the laser therapy is used to stimulate tissue repair or reduce inflammation. The exact mechanism of action is not well understood, but it is thought to involve the activation of various cellular pathways that promote healing.","oneSentence":"This drug combines a sham injection with laser therapy, which is a non-pharmacological treatment approach.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:09.324Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of psoriasis"}]},"trialDetails":[{"nctId":"NCT06007690","phase":"PHASE3","title":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","status":"RECRUITING","sponsor":"Aura Biosciences","startDate":"2023-12-06","conditions":"Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma","enrollment":100},{"nctId":"NCT03941587","phase":"NA","title":"Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment","status":"COMPLETED","sponsor":"Singapore National Eye Centre","startDate":"2021-02-01","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT05800353","phase":"NA","title":"Nd:YAG Laser Vitreolysis for Symptomatic Vitreous Floaters","status":"COMPLETED","sponsor":"Dongyang People's Hospital","startDate":"2022-11-22","conditions":"Weiss Ring","enrollment":70},{"nctId":"NCT07108400","phase":"NA","title":"Efficacy of a Combination of Ultrasound-guided Intra-articular Injections of Hyaluronic Acid, High-power Laser Therapy and Rehabilitation on Functioning in Patients Affected by Hip Osteoarthritis.","status":"RECRUITING","sponsor":"De Sire Alessandro","startDate":"2022-03-17","conditions":"Hip Osteoarthritis","enrollment":57},{"nctId":"NCT04919499","phase":"PHASE1, PHASE2","title":"A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-07-30","conditions":"Diabetic Retinopathy","enrollment":46},{"nctId":"NCT04824612","phase":"NA","title":"Photobiomodulation and the Intralesional Administration of Corticoid in the Keloid Surgery.","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2021-08-30","conditions":"Keloid, Cicatrix","enrollment":4},{"nctId":"NCT06510673","phase":"NA","title":"Extracorporeal Shock Wave Therapy Versus High Power LASER Therapy for the Treatment of Females With Calcaneal Spur","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-10-01","conditions":"Calcaneal Spur","enrollment":72},{"nctId":"NCT06128590","phase":"NA","title":"Photobiomodulation for Controlling Pre-Local Anesthetic Injection Pain","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2023-02-15","conditions":"Fear Needles","enrollment":50},{"nctId":"NCT04424290","phase":"PHASE1, PHASE2","title":"HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-06-12","conditions":"Diabetic Retinopathy","enrollment":45},{"nctId":"NCT05734248","phase":"NA","title":"Fractional Laser Drug Delivery of a Local Anesthetic","status":"COMPLETED","sponsor":"University Hospital, Ioannina","startDate":"2023-02-06","conditions":"Aging, Face; Atrophy","enrollment":25},{"nctId":"NCT05720000","phase":"NA","title":"Use of Red Light Emitting Diode (LED) and Polydioxanone Thread in Glabellar Wrinkles","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2023-01-25","conditions":"Skin Wrinkling, Edema","enrollment":40},{"nctId":"NCT02634333","phase":"PHASE3","title":"Anti-VEGF Treatment for Prevention of PDR/DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2016-01","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":399},{"nctId":"NCT00309192","phase":"PHASE3","title":"Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2006-04","conditions":"Diabetes Mellitus, Macular Edema","enrollment":292},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT05582577","phase":"PHASE2, PHASE3","title":"Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-10-15","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT02120950","phase":"PHASE4","title":"Aflibercept in Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-29","conditions":"Neovascular Macular Degeneration","enrollment":333},{"nctId":"NCT02229175","phase":"PHASE2, PHASE3","title":"Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2021-01-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT04464694","phase":"PHASE4","title":"Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-01","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":142},{"nctId":"NCT01788475","phase":"NA","title":"Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2013-02-22","conditions":"Diabetic Macular Edema","enrollment":3},{"nctId":"NCT03809416","phase":"NA","title":"Combined LASERs and PRP for Postacne Scars","status":"COMPLETED","sponsor":"DEKA S.r.l.","startDate":"2018-10-01","conditions":"Atrophic Acne Scar","enrollment":32},{"nctId":"NCT00444600","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":691},{"nctId":"NCT01795209","phase":"PHASE4","title":"Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2013-01","conditions":"Branch Retinal Vein Occlusion, Macular Edema","enrollment":19},{"nctId":"NCT03143192","phase":"PHASE2, PHASE3","title":"Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser","status":"COMPLETED","sponsor":"Keyvan Koushan","startDate":"2017-03-08","conditions":"Diabetic Macular Edema","enrollment":31},{"nctId":"NCT02650050","phase":"NA","title":"Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2016-01-19","conditions":"Macular Edema, Mellitus Diabetes","enrollment":5},{"nctId":"NCT01846273","phase":"PHASE4","title":"Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08-07","conditions":"Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":321},{"nctId":"NCT00464685","phase":"PHASE2","title":"Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-05-01","conditions":"Diabetic Macular Edema","enrollment":253},{"nctId":"NCT02259088","phase":"PHASE3","title":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-05","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":384},{"nctId":"NCT02348918","phase":"PHASE2","title":"Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allegro Ophthalmics, LLC","startDate":"2014-10-13","conditions":"Diabetic Macular Edema","enrollment":218},{"nctId":"NCT03759860","phase":"PHASE4","title":"Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema","status":"UNKNOWN","sponsor":"CynosureLutronic","startDate":"2018-01-08","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT00605280","phase":"PHASE2, PHASE3","title":"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Macular Edema Associated With Diabetes Mellitus","enrollment":317},{"nctId":"NCT02007174","phase":"","title":"Bevacizumab Injection for Recurrent Pterygium","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2012-03","conditions":"Recurrent Pterygium","enrollment":38},{"nctId":"NCT02857491","phase":"NA","title":"Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-07","conditions":"Proliferative Diabetic Retinopathy","enrollment":90},{"nctId":"NCT02897583","phase":"NA","title":"YAG Vitreolysis for Floaters","status":"COMPLETED","sponsor":"Ophthalmic Consultants of Boston","startDate":"2015-02","conditions":"Weiss Ring, Floaters, Posterior Vitreous Detachment","enrollment":52},{"nctId":"NCT00445003","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":333},{"nctId":"NCT00336323","phase":"PHASE2","title":"A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2006-06","conditions":"Diabetic Retinopathy","enrollment":121},{"nctId":"NCT02194634","phase":"PHASE3","title":"Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2014-07","conditions":"Diabetic Macular Edema","enrollment":248},{"nctId":"NCT01319188","phase":"PHASE4","title":"Ranibizumab and the Risk of Arterial Thromboembolic Events","status":"TERMINATED","sponsor":"Ural State Medical University","startDate":"2010-06","conditions":"Age-related Macular Degeneration, Coronary Artery Disease, Cerebrovascular Disorders","enrollment":380},{"nctId":"NCT00344968","phase":"PHASE3","title":"Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Alimera Sciences","startDate":"2007-09","conditions":"Diabetic Macular Edema","enrollment":956},{"nctId":"NCT00687804","phase":"PHASE3","title":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Diabetic Macular Edema","enrollment":345},{"nctId":"NCT01020747","phase":"PHASE1","title":"Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-11","conditions":"Recurrent Respiratory Papillomatosis","enrollment":20},{"nctId":"NCT00989989","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Diabetic Macular Edema","enrollment":396},{"nctId":"NCT01131585","phase":"PHASE3","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":128},{"nctId":"NCT00599222","phase":"PHASE3","title":"The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2008-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":100},{"nctId":"NCT00284050","phase":"PHASE2","title":"Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Diabetic Macular Edema","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo"],"phase":"phase_3","status":"active","brandName":"Sham injection + laser","genericName":"Sham injection + laser","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sham injection is a control intervention used in clinical trials for conditions such as Weiss Ring, Floaters, and Diabetic Retinopathy, often in conjunction with laser treatment. The exact mechanism of Sham injection is unknown, as it is classified as a compound solution of sodium chloride, similar to Ringer's injection, but its specific formulation and effects are not well-documented.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}